Skip to main content

Advertisement

Table 2 Patients receiving caspofungin treatment

From: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

Indication for IV caspofungin therapy Monotherapy
(N= 85) n (%)
Combination
therapy
(N = 18) n (%)
Overall
(N = 103) n (%)
Caspofungin first-line therapy 15 (17.6) 5 (27.8) 20 (19.4)
Caspofungin salvage therapy 70 (82.4) 13 (72.2) 83 (80.6)
   Clinical refractory to first-line antifungal 48 (68.6) 10 (76.9) 58 (69.0)
   Microbiological refractory to first-line antifungal 6 (8.6) 1 (7.7) 7 (8.4)
   Toxicity    
• Nephrotoxicity to first-line antifungal 2 (2.9) 1 (7.7) 3 (3.6)
• Other toxicity 6 (8.6) 0 6 (7.2)
   Other* 7 (10.0) 1 (7.7) 8 (9.6)
   Not reported 1(1.4) 0 1 (1.2)
  1. *Other reasons include: Severe disease requiring combination therapy, prophylaxis, elevated Aspergillus antigen, empirical therapy, elevated creatinine